Landiolol + Norepinephrine

Landiolol + norepinephrine is a combination therapy used primarily in critical care settings, particularly for patients with atrial tachyarrhythmias who also require hemodynamic support. Landiolol is an ultra-short-acting, highly beta-1 selective adrenergic receptor antagonist, while norepinephrine is a vasopressor that helps maintain blood pressure.\n\nThis combination is particularly valuable in intensive care settings where patients experience supraventricular tachycardias (including atrial fibrillation and atrial flutter) but also require hemodynamic support due to conditions like cardiogenic shock or sepsis. The search results show that this combination has been successfully used in critical care patients, with landiolol effectively reducing heart rate while norepinephrine provides necessary circulatory support[5].\n\n## Pharmacological Properties\n\nLandiolol is characterized by:\n- Ultra-short half-life (approximately 4 minutes)\n- High beta-1 selectivity (ratio of β1/β2: 255/1)\n- Minimal impact on blood pressure\n- Rapid onset of action (heart rate reduction within 1 hour)[1]\n\nNorepinephrine provides:\n- Vasoconstriction\n- Increased blood pressure\n- Circulatory support in shock states\n\n## Clinical Applications\n\nThe combination is particularly useful in:\n\n**Cardiogenic Shock with Tachyarrhythmias**\nPatients with cardiogenic shock often develop tachyarrhythmias that further compromise cardiac output. The combination allows for heart rate control while maintaining blood pressure[5].\n\n**Septic Shock with Atrial Fibrillation**\nIn septic patients who develop new-onset atrial fibrillation, the combination can control heart rate while supporting circulation[1].\n\n**Post-Operative Cardiac Care**\nUsed in post-cardiac surgery patients who develop tachyarrhythmias but require hemodynamic support.\n\n## Dosing Considerations\n\nLandiolol is typically administered at lower doses when combined with vasopressors:\n- Starting doses of 1-10 μg/kg/min are recommended for patients with reduced ventricular ejection fraction (25-50%)[2]\n- For patients with cardiogenic shock, low-dose landiolol (1.5 μg/kg/min) has been shown to reduce heart rate by approximately 11% without adversely affecting blood pressure or cardiac index[5]\n- Dose titration is based on heart rate response and hemodynamic stability\n\nNorepinephrine dosing is typically:\n- 0.5 μg/kg/min or higher, titrated to maintain adequate blood pressure[5]\n\n## Safety Profile\n\nThe combination appears to be well-tolerated in critically ill patients:\n- Landiolol's ultra-short half-life allows for rapid dose adjustments if hemodynamic deterioration occurs\n- The high beta-1 selectivity minimizes bronchospasm risk\n- Careful monitoring is essential, particularly for hypotension and bradycardia[3]\n\n## Regulatory Status\n\nLandiolol (brand name Rapiblyk) received FDA approval in November 2024 for the treatment of supraventricular tachycardia in hospital critical care settings[6]. The combination with norepinephrine is used in clinical practice but is not specifically FDA-approved as a fixed combination.\n\nThis combination represents an important therapeutic approach for managing complex patients who require both rate control and hemodynamic support in critical care settings.